Alon Ben David

TL;DR: This study presents an approach for the simultaneous generation of highly specific and neutralizing MAbs against botulinum serotypes A, B, and E in a single process that relies on immunization of mice with a trivalent mixture of recombinant C-terminal fragment of each of the three neurotoxins followed by differential robotic hybridoma screening.

TL;DR: In this paper, the authors describe the development of an in vitro RBD-ACE2 binding assay and its application to identify inhibitors of the interaction of the SARS-CoV-2 RBD to ACE2 by the high-throughput screening of two compound libraries (LOPAC®1280 and DiscoveryProbeTM) three compounds, heparin sodium, aurintricarboxylic acid (ATA), and ellagic acid, were found to exert an effective binding inhibition.

TL;DR: An innovative in vitro assay to mimic two fundamental steps in botulinum intoxication: receptor binding and catalytic activity is developed and has the potential to be considered, after validation, as a replacement to the mouse assay for quantitating neutralizing antibody concentrations in pharmaceuticalbotulinum antitoxin preparations.

TL;DR: In vivo inhibition of BoNT/A intoxication by HC/A is demonstrated here for the first time, presumably due to a blockade of the neurotoxin protein receptor SV2, suggesting complementary mechanisms of protection consisting of toxin neutralization by antibodies and receptor blocking byHC/A.

TL;DR: This work demonstrates for the first time the therapeutic efficacy of equine-derived anti-ricin F(ab’)2 antibodies against lethal pulmonary and systemic ricin exposures in swine and can serve as the basis for the formulation of post-exposure countermeasures against ricin poisoning in humans.